Aelis Farma is specialized in the research and development of drugs for the treatment of major disorders of the Central Nervous System (CNS). The company has 2 products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome, Fragile X syndrome, Subjective Memory Impairment (SMI) and Alzheimer's disease).

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-10-02	€0.8750	-1.02%	5,791
26-10-01	€0.8840	-1.78%	1,716
26-09-30	€0.9000	+1.12%	3,335
26-09-29	€0.8900	-3.26%	17,610
26-09-28	€0.9200	0.00%	8,449

Real-time Euronext Paris

More quotes

Annual profits - Rate of surprise

Company calendar

Market Closed - Euronext Paris 11:55:00 2026-10-02 EDT			5-day change	1st Jan Change
0.8750 ^EUR	-1.02%		-4.89%	-22.22%

09-15	Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-16	Aelis continues development of AEF0217 in Down syndrome, shares rise

Market Cap	11.9M 13.39M 11.1M 10.12M 19.09M 1.29B 19.27M 134M 52.07M 658M 50.27M 49.18M 2.11B	P/E 2024	-3.61x	P/E 2025	-2.39x
Enterprise Value	9.79M 11.02M 9.14M 8.33M 15.71M 1.06B 15.86M 111M 42.87M 542M 41.39M 40.49M 1.74B	EV / Sales 2024	3.46x	EV / Sales 2025	6.33x
Free-Float	63.56%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Euronext Paris	AELIS	Real-time
Deutsche Boerse AG	69O	Delayed
Boerse Muenchen	69O	Real-time
Börse Stuttgart	69O	Delayed

09-15	Aelis Farma SA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
07-16	Aelis continues development of AEF0217 in Down syndrome, shares rise
07-16	Aelis Farma Receives Positive Recommendation from Independent Data Monitoring Committee to Continue Phase 2b Study of AEF0217 in People with Down Syndrome Without Modification	CI
04-23	Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-07	Aelis Farma Receives ?458,000 Grant Under France 2030 in Nouvelle-Aquitaine to Support Development of Its Program in Obesity and Associated Metabolic Diseases	CI
03-23	Stocks to watch today
03-23	Aelis Farma begins patient enrollment for clinical trial
03-23	Aelis Farma Launches Phase 2B Trial for Down Syndrome Impairments Treatment	MT
03-21	Aelis Farma Announces Successful Start of Recruitment of Phase 2B Clinical Trial with Aef0217 for Treatment of Behavioral and Cognitive Impairments of People with Down Syndrome	CI
01-12	Aelis Farma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for AEF0217 in Down Syndrome	CI
12-02	European Green Light for Aelis Farma's Phase 2B Trial in Down Syndrome
12-02	Aelis Farma Obtains Regulatory Approval of the Phase 2B Trial with AEF0217 in People with Down Syndrome	CI
25-09-25	Aelis Farma availability of 2025 half-year financial report	RE

Aelis Farma Stock

Stocks

AELIS

FR0014007ZB4

Pharmaceuticals

Valuation: Aelis Farma

Chart: Aelis Farma

Latest news: Aelis Farma

Analysts' recommendations: Aelis Farma

Press Releases: Aelis Farma

News in other languages: Aelis Farma

Quotes and Performance

Price Extremes

Managers and Directors: Aelis Farma

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

09-24	Aelis Farma: Availability of the 2026 Half-Year Financial Report	BU
09-15	Aelis Farma Reports 2026 Half-Year Financial Results and Presents Progress and Development Outlook	BU
07-16	Aelis Farma Receives a Positive Recommendation From the Independent Data Monitoring Committee to Continue the Phase 2b Study of AEF0217 in People With Down Syndrome Without Modification	BU
06-22	Aelis Farma: Availability of the Description of the Share Buyback Program	BU
06-04	Results of Aelis Farma Combined General Meeting of June 3, 2026	BU

09-24	Aelis Farma : Mise à disposition du rapport financier semestriel 2026
09-15	Aelis Farma publie ses résultats financiers semestriels 2026 et présente ses avancées et perspectives de développement
09-14	Agenda Zonebourse des résultats de sociétés : le 15 septembre 2026
09-12	Agenda des résultats de la semaine : Bolloré, Virbac, Robertet et d'autres valeurs moyennes au programme
07-16	Aelis poursuit le développement de l'AEF0217 dans la trisomie 21, le titre monte

1 day	-1.02%
1 week	-4.89%
Current month	-2.78%
1 month	-12.50%
3 months	-16.67%
6 months	-32.69%
Current year	-22.22%

1 week	0.87	0.94
1 month	0.87	1.02
Current year	0.87	2.3
1 year	0.87	2.3
3 years	0.67	13.6
5 years	0.67	14.48
10 years	0.67	14.48

Manager	Title	Age	Since
Pier Vincenzo Piazza CEO	Chief Executive Officer	65	2016-12-31
Marie Line Lefevre DFI	Director of Finance/CFO	-	-
Helle Mengel CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Pier Vincenzo Piazza BRD	Director/Board Member	65	2016-12-31
Anders Gersel Pedersen CHM	Chairman	75	2019-12-31
Brahim Guetarni BRD	Director/Board Member	49	2020-12-31

Date	Insider	Type	Quantity	% Market Cap.
9/1/23	Vincenzo Piazza Pier	Buy	200	0.0016%
8/4/23	Vincenzo Piazza Pier	Buy	10	0.0001%
7/12/23	Vincenzo Piazza Pier	Buy	20	0.0002%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AELIS FARMA	-1.02%	-4.89%	-24.89%	-93.49%	13.39M
ELI LILLY AND COMPANY	-0.61%	-3.43%	+39.40%	+112.31%	1,019B
JOHNSON & JOHNSON	-1.02%	-5.60%	+37.67%	+65.02%	617B
ABBVIE INC.	+1.11%	-0.58%	+11.10%	+77.28%	464B
MERCK & CO., INC.	+0.34%	-3.01%	+61.21%	+40.71%	356B
ROCHE HOLDING AG	-0.95%	-4.05%	+21.60%	+39.37%	333B
NOVARTIS AG	-1.46%	-2.89%	+11.84%	+24.60%	267B
ASTRAZENECA PLC	-1.35%	-5.43%	-4.69%	+8.40%	244B
AMGEN INC.	-1.04%	-2.79%	+35.52%	+51.34%	218B
GILEAD SCIENCES, INC.	-1.87%	-4.10%	+30.92%	+95.33%	179B
Average	-0.31%	-3.54%	+21.97%	+42.09%	369.72B
Weighted average by Cap.	+0.42%	-3.33%	+30.52%	+68.96%

	2024	2025
Net sales	5.56M 6.26M 5.19M 4.73M 8.92M 602M 9.01M 62.82M 24.34M 308M 23.5M 22.99M 987M	2.08M 2.35M 1.95M 1.77M 3.34M 225M 3.37M 23.54M 9.12M 115M 8.81M 8.62M 370M
Net income	-7.46M -8.39M -6.96M -6.34M -11.96M -807M -12.07M -84.22M -32.63M -412M -31.51M -30.82M -1.32B	-6.43M -7.24M -6.01M -5.47M -10.32M -696M -10.42M -72.67M -28.16M -356M -27.19M -26.6M -1.14B
Net Debt	-7.97M -8.97M -7.44M -6.78M -12.78M -862M -12.9M -89.99M -34.87M -441M -33.67M -32.94M -1.41B	-2.1M -2.37M -1.96M -1.79M -3.37M -228M -3.41M -23.75M -9.2M -116M -8.89M -8.69M -373M